Picture BIO Deutschland German Biotech Days 2016 Leipzig April 600x60px
Document › Details

4-Antibody AG. (3/16/10). "Press Release: 4-Antibody Announces Long-term Collaboration with Boehringer Ingelheim for Therapeutic Antibodies". Basel.

Organisations Organisation 4-Antibody AG
  Group Agenus (Group)
  Organisation 2 Boehringer Ingelheim (Group)
Products Product antibody technology
  Product 2 MAb, human, fully
Index term Index term Boehringer–4-Antibody: therapeutic antibodies, 201003– collab up to €177.5m incl upfront + milestones discovery + developm fully human antibodies
Person Person Grawunder, Ulf (4-Antibody 200810 CSO before CEO + founder)

4-Antibody AG today announces a major long-term collaboration with Boehringer Ingelheim to discover and to develop fully human therapeutic antibodies for a number of targets in various disease indications. 4-Antibody will use its proprietary and unencumbered Hu-PAC® and Retrocyte Display® technologies for the discovery and development of fully human antibodies against novel targets nominated by Boehringer Ingelheim. 4-Antibody AG will receive payments of up to EUR 177.5 million (CHF 266 million) including upfront and milestone payments from Boehringer Ingelheim upon achievement of certain clinical development milestones. Further financial details were not disclosed.

Dr. Ulf Grawunder, co-founder and CSO of 4-Antibody AG, said “This is a landmark agreement for 4-Antibody. We are delighted to commence a long-term collaboration with Boehringer Ingelheim and to apply the strength of 4-Antibody’s fully human antibody discovery and engineering platforms to create valuable potential new drug candidates. Our unique and unencumbered technology capabilities allow the efficient generation of novel or improved fully human antibodies against any target class for our collaboration partners and for our own clinical development pipeline.”

- ends -

About 4-Antibody AG

4-Antibody AG is a privately held Swiss Biotech company active in the area of therapeutic
antibody drug development. 4-Antibody AG has developed a portfolio of powerful, proprietary
antibody discovery and engineering platforms, including the Hu-PAC® and the Retrocyte Display® technologies. 4-Antibody AG owns four patent families related to therapeutic antibody discovery platforms and products, including more than a dozen of granted patents worldwide. The company has 40 employees working at its headquarter in Basel, Switzerland, and its subsidiary in Jena, Germany.

Record changed: 2016-03-20


Picture BIO Deutschland German Biotech Days 2016 Leipzig April 600x60px

More documents for Agenus (Group)

To subscribe to our free, monthly newsletter for the life sciences in German-speaking Europe (DE, AT & CH), please send an e-mail to and simply fill the subject line with the word »LSG newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at (European life sciences) and (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at (life sciences in German-speaking Europe) and (worldwide mass spectrometry)


Picture [iito] Roadshow Season Spring 2016 JPMorgan Healthcare 2017 600x560px

» top


Picture [iito] Roadshow Spring 2016 Offer 120x180px Picture EBD Group ChinaBio Partnering Forum 2016 CBPF Suzhou May 120x180px Picture [LSE] – The Business Web Portal 120x600px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px